Stay updated on Insulin Glargine vs Lantus® in Type 1 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Insulin Glargine vs Lantus® in Type 1 Diabetes Clinical Trial page.

Latest updates to the Insulin Glargine vs Lantus® in Type 1 Diabetes Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for INSTRIDE 1 is now displayed instead of an access-denied page, with detailed information about the insulin glargine comparison study and its results measures.SummaryDifference100%

- Check13 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the study record page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA sitewide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer revision advances from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error screen, replacing the previous study record content and navigation. This indicates an access restriction rather than a substantive update to the study data.SummaryDifference16%

Stay in the know with updates to Insulin Glargine vs Lantus® in Type 1 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Insulin Glargine vs Lantus® in Type 1 Diabetes Clinical Trial page.